Cruentaren, a new antifungal salicylate-type macrolide from Byssovorax cruenta (Myxobacteria) with inhibitory effect on mitochondrial ATPase activity: Fermentation and biological properties

55Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The novel macrolide cruentaren A was produced at levels up to 3.2 mg/liter by cultures of the myxobacterium Byssovorax cruenta. The new compound strongly inhibited the growth of yeasts and filamentous fungi and showed high cytotoxicity against L929 mouse fibroblast cells. A minor co-metabolite of cruentaren A, named cruentaren B, and identified as a six-membered lactone isomer of cruentaren A, showed only marginal cytotoxicity and no antifungal activity. Cruentaren A inhibited F0F1 mitochondrial ATP-hydrolysis in submitochondrial particles of yeasts and beef heart. © Japan Antibiotics Research Association.

Cite

CITATION STYLE

APA

Kunze, B., Steinmetz, H., Höfle, G., Huss, M., Wieczorek, H., & Reichenbach, H. (2006). Cruentaren, a new antifungal salicylate-type macrolide from Byssovorax cruenta (Myxobacteria) with inhibitory effect on mitochondrial ATPase activity: Fermentation and biological properties. Journal of Antibiotics, 59(10), 664–668. https://doi.org/10.1038/ja.2006.89

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free